Centre for Drug Development: Strategy and portfolio

Our strategic priorities

Our ambition is to accelerate the delivery of the next generation of medicines to the patients who need them.

As the world's only charity-funded drug development facility, our strategy is uniquely focused by the drive for patient benefit. We are particularly interested in innovative projects, and our strengths are in:

  • First in class therapies
  • First in human clinical trials
  • Projects where we can use pharmacodynamic and stratification biomarker technologies to identify and progress new treatments which have the greatest potential for patient benefit

We maintain a broad portfolio across therapeutic modalities including antibodies, imaging agents, cell therapies, vaccines and targeted small molecules.

Our pipeline

PortfolioOur development portfolio contains 10 small molecule agents and 10 biologicals as of September 2017. Download the full pipeline or browse the agents below.

 

Agent

Target or technology

Partnerships

Indications

Status

SnMP

HO1

Solid, others tbc

Exploratory

STK-01

HPG-docetaxel

Bladder

Exploratory

Tb535H

T-cell engaging antibody (tribody)
5T4, CD3

Solid tumours, mesothelioma

Due diligence

SCIB2

Vaccine
NY-ESO-1

Solid, lung

Due diligence

MEDI3039

Recombinant protein
TrailR2

Solid, colorectal, lung

Exploratory

Agent

Target or technology

Partnerships

Indications

Status

BT1718

MT1-MMP

Solid, lung, sarcoma, breast

Phase 1

LY3143921

Cdc7

Solid, colorectal, ovarian

Phase 1

AZD3965

MCT1

Solid, lymphoma, B cell, DLBCL

Phase 1

ASTVAC2

Vaccine
LAMP, hTERT

Lung

Phase 1

BI-1206

Antibody
CD32b, FcγRIIB

Lymphoma, B cell, CLL

Phase 1

MOv18 

Antibody
α-folate R

Solid

Phase 1

1RG CART

Cell therapy
GD2

Neuroblastoma

Phase 1

Vandetanib/ Selumetinib

EGFR, VEGFR, MEK

Solid, lung

Completed phase 1

AT9283

Aurora Kinase

Paediatric solid

Completed phase 1

mIBG

NAT nor-adrenalin transporter

Neuroblastoma

Phase 2

Agent

Target or technology

Partnerships

Indications

Status

AT13148

AGC, ROCK

Solid

Completed phase 1

Dl-B4

Antibody
CD19

Lymphoma, B cell, CLL

Completed phase 1

AMG319

p110d PI3K

Head and neck oropharyngeal

Completed phase 2

Portfolio news

First patient treated in AZD3965 expansion phase

July 2018
The expansion phase of AZD3965, a first in class phase 1 trial sponsored by our Centre for Drug Development and in partnership with AstraZeneca, has now opened. AZD3965 targets the monocarboxylate transporter 1 (MCT1), disrupting lactate transport and affecting cellular metabolism. The first patient from the selected patient population, the tumour type Diffuse Large B Cell Lymphoma, was dosed with the RP2D in May at Leicester Royal Infirmary, beginning the expansion phase which is due to be carried out in seven centres (including 6 ECMCs) across the UK.

Our track record of marketed drugs

Abiraterone

Discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, and developed by the Centre for Drug Development before licensing to Janssen Biotech, Abiraterone acetate (Zytiga®) is a hormonal therapy for prostate cancer.

Pemetrexed

Pemetrexed (Alimta®) is indicated for pleural mesothelioma and non-small cell lung cancer.
 
 

Temozolomide

One of our earliest successes, discovered by CRUK-funded scientists and developed by the CDD in the 1980s and 90s, Temozolomide (Temodal ®) is used worldwide as the frontline drug for glioblastoma and astrocytoma.

Etoposide phosphate

Etoposide phosphate (Etopophos®) is a drug used in small cell lung cancer and testicular tumours that no longer respond to other treatments.
 

Rucaparib

Discovered by CRUK scientists at the Northern Institute for Cancer Research in a programme built on breakthroughs from CRUK's basic science, we progressed the early development of the PARP inhibitor Rucaparib (Rubraca®).

Formestane

Formestane (Lentaron®) is a selective aromatase inhibitor that was indicated for the use in breast cancer, but was subsequently superseded by third-generation inhibitors such as letrozole.

Contact us

We are looking to partner with leading pharmaceutical and biotechnology companies and academic scientists who require resource, capabilities or expertise to develop new agents for the treatment of cancer.

Get in touch

Share this page